1. Home
  2. XRTX

as of 06-04-2026 3:40pm EST

$2.19
$0.03
-1.35%
Stocks Health Care Pharmaceuticals and Biotechnology Nasdaq

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

Founded: 2011 Country:
Canada
Canada
Employees: N/A City: N/A
Market Cap: 4.3M IPO Year: 2018
Target Price: N/A AVG Volume (30 days): 33.2K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.34 - $3.60 Next Earning Date: 05-15-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: